Current Status of Pseudomonas aeruginosa Vaccine

ISSN: 1873-4316 (Online)
ISSN: 1389-2010 (Print)

Volume 18, 15 Issues, 2017

Download PDF Flyer

Current Pharmaceutical Biotechnology

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 152nd of 255 in Pharmacology & Pharmacy
  • 213th of 290 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Zeno Foldes-Papp
Urban Clinical Center Soltau
University teaching hospital of Hamburg

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.802
5 - Year: 2.327

Current Status of Pseudomonas aeruginosa Vaccine

Current Pharmaceutical Biotechnology, 14(11): 951-959.

Author(s): Lessandra Michelim, Gregory Saraiva Medeiros and Alexandre P Zavascki.

Affiliation: Infectious Diseases Service, University of Caxias do Sul - Hospital de Geral. 255 Prof Antonio Vignolli St, Caxias do Sul, 95070-561, Brazil.


Pseudomonas aeruginosa is one of the major pathogens responsible for a wide variety of severe nosocomial and community acquired infections. Numerous vaccine candidates and several monoclonal antibodies have been developed over the past 40 years but only a few have reached clinical trials and none of these vaccine candidates has obtained market authorization. The understanding of P. aeruginosa pathogenesis and its virulence factors is essential in the identification of immunogens that can be used for a P. aeruginosa vaccine. This review summarizes the present status of vaccine development for this important pathogen.


Cystic fibrosis, Clinical trials, Hospital infections, Immunity, Pseudomonas aeruginosa, Vaccines.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 11
First Page: 951
Last Page: 959
Page Count: 9
DOI: 10.2174/1389201014666131226143923
Price: $58
Pharmaceutical Microbiology 2017

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science